培力藥品公司是一家專注於健保給付處方藥（學名藥）市場的中小型國產藥廠，面對健保制度主導製藥產業、國際藥廠以雄厚的資金與優異的研發能力進攻台灣市場、目標市場面臨大量國產藥廠低價掠奪，培力藥品公司如何在產業高度競爭下，持續成長並選擇適合的營運模式，此課題正考驗著公司領導者郭榮昌董事長的經營智慧。

Pei Li Pharm is a small- to medium-scale domestic pharmaceutical company focused on the research and production of prescription drugs (generic drugs) covered by the National Health Insurance (NHI) scheme. Because of the NHI’s dominance of the pharmaceutical industry, international pharmaceutical companies enter the Taiwan market with significant capital and outstanding research and development abilities. By contrast, domestic pharmaceutical companies adopt a low-price policy to retain their market share. In this highly competitive industry, the continued growth of Pei Li Pharm, and adoption of an appropriate operating model, is dependent on the chairman’s (Rong-Chang Guo) business intelligence.